The U.S. FDA has approved Aduhelm (aducanumab) developed by Biogen, Cambridge, Massachusetts, for the treatment of Alzheimer’s. Aduhelm was approved using the ‘accelerated approval pathway’.
The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, won ‘The Best COVID-19 Responder’ at the OBN 2020 Awards. The award recognises the company’s outstanding contribution to the fight against COVID-19.
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, has received a patent from the Japan Patent Office for their oncolytic virus (OV) backbone VVcopTK-RR- that encodes one or more immune checkpoint inhibitors (ICIs).
Lunaphore Technologies, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, has appointed Matthias Weber, former President of Leica Biosystems, to its Board of Directors. Weber has been appointed to represent the interests of strategic investor PHC Holdings Corporation (PHCHD), who previously invested in Lunaphore through a Series C financing round in 2020.
Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, has completed a US$47 million financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform […]
Aptamer Group, the developer of Optimer Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, have entered into a strategic collaboration agreement. The agreement is to develop Optimer-drug conjugates for targeted drug delivery combining Aptamer Group’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.
Byondis has reported positive topline results from the Phase III TULIP study, a multi-centre, open-label, randomized clinical trial. The trial compared the efficacy and safety of the company’s antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) to physician’s choice treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer.
Celemics has partnered with Strand Life Sciences to develop a bioinformatics solution capable of providing users with an accelerated means of producing high-quality, in-class clinical genomics reports and enabling a complete sample-to-answer solution, including assayspecific variant filters.
Algorics, a provider of biostatistics and programming solutions for the pharmaceutical and biotechnology industry, has acquired Domain Clinical Data Sciences (DCDS), a clinical data services organisation based in India.
Abviris Deutschland, a biotech company, has received an injection of €2 million from existing investors to speed up expansion. The move comes after the publication of highly promising results for its pioneering immunoassay biomarker as an aid in the early diagnosis of head, neck and anogenital cancers caused by human papilloma viruses (HPV).
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
